Qinglian Wen

Qinglian Wen


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
QYQingfan Yang
Qingfan Yang
YCYu Chen
Yu Chen
RGRui Guo
Rui Guo
YDYalan Dai
Yalan Dai
LTLiyao Tang
Liyao Tang
QWQinglian Wen
Qinglian Wen
Gastric cancer has developed as a very common gastrointestinal tumors, with recent effective advancements in the diagnosis and treatment of early gastric cancer. However, the prognosis for gastric cancer remains poor. As a result, there is in sore need of better understanding the mechanisms of gastric cancer development and progression to improve existing diagnostic and treatment options. In recent years, epigenetics has been recognized as an important contributor on tumor progression. Epigenetic changes in cancer include chromatin remodeling, DNA methylation and histone modifications. An increasing number of studies demonstrated that noncoding RNAs (ncRNAs) are associated with epigenetic changes in gastric cancer. Herein, we describe the molecular interactions of histone modifications and ncRNAs in epigenetics. We focus on ncRNA-mediated histone modifications of gene expression associated with tumorigenesis and progression in gastric cancer. This molecular mechanism will contribute to our deeper understanding of gastric carcinogenesis and progression, thus providing innovations in gastric cancer diagnosis and treatment strategies.

1 January 2020 in International Journal of Biological Sciences
Verified
Journal Article
Open access
DLDan Li
Dan Li
SXShixin Xiang
Shixin Xiang
JSJing Shen
Jing Shen
MXMingtao Xiao
Mingtao Xiao
YZYueshui Zhao
Yueshui Zhao
QWQinglian Wen
Qinglian Wen
Objectives: B7 family members were identified as co-stimulators or co-inhibitors of the immune response and played important roles in cancer immunotherapy; however, their dysregulation in gastric cancer is still unclear.

1 July 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
XZXinyue Zhang
Xinyue Zhang
JGJinan Guo
Jinan Guo
Parham Jabbarzadeh KaboliParham Jabbarzadeh Kaboli
Parham Jabbarzadeh Kaboli
QZQijie Zhao
Qijie Zhao
SXShixin Xiang
Shixin Xiang
QWQinglian Wen
Qinglian Wen
Objective: The Warburg effect, also known as aerobic glycolysis, plays a dominant role in the development of gastrointestinal (GI) cancers. In this study, we analyzed the expression of key genes involved in the Warburg effect in GI cancers and investigated the effect of suppressing the Warburg effect in vitro in liver cancer cell lines. Methods: The Cancer Genome Atlas (TCGA) RNA-Seq data were used to determine gene expression levels, which were analyzed with GraphPad Prism 7.00. Genetic alterations were queried with cBioPortal. The influence of the Warburg effect on liver cancer cell viability, migration and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity was determined by means of MTT, transwell and GAPDH activity assays. Results: The levels of expression of genes associated with the Warburg effect were increased in tumors. To our knowledge, this is the first report of upregulated expression of CUEDC2, HMGB2, PFKFB4, PFKP and SIX1 in liver cancer. Clinically, overexpression of these genes was associated with significantly worse overall survival of liver cancer patients. In vitro, selective inhibition of GADPH suppressed the growth and metastasis of Huh-7, Bel7404 and Hep3B hepatocellular carcinoma cell lines. Conclusion: The Warburg effect may play an important role in GI cancers, especially in liver cancer.

7 December 2020 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
SXShixin Xiang
Shixin Xiang
YMYongshun Ma
Yongshun Ma
JSJing Shen
Jing Shen
YZYueshui Zhao
Yueshui Zhao
XWXu Wu
Xu Wu
ZXZhangang Xiao
Zhangang Xiao
5-Methylcytosine (m5C) is a kind of methylation modification that occurs in both DNA and RNA and is present in the highly abundant tRNA and rRNA. It has an important impact on various human diseases including cancer. The function of m5C is modulated by regulatory proteins, including methyltransferases (writers) and special binding proteins (readers). This study aims at comprehensive study of the m5C RNA methylation-related genes and the main pathways under m5C RNA methylation in gastrointestinal (GI) cancer. Our result showed that the expression of m5C writers and reader was mostly up-regulated in GI cancer. The NSUN2 gene has the highest proportion of mutations found in GI cancer. Importantly, in liver cancer, higher expression of almost all m5C regulators was significantly associated with lower patient survival rate. In addition, the expression level of m5C-related genes is significantly different at various pathological stages. Finally, we have found through bioinformatics analysis that m5C regulatory proteins are closely related to the ErbB/PI3K–Akt signaling pathway and GSK3B was an important target for m5C regulators. Besides, the compound termed streptozotocin may be a key candidate drug targeting on GSK3B for molecular targeted therapy in GI cancer.

3 November 2022 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
YCYu Chen
Yu Chen
QYQingfan Yang
Qingfan Yang
JXJinrun Xu
Jinrun Xu
LTLiyao Tang
Liyao Tang
YZYan Zhang
Yan Zhang
ZXZhangang Xiao
Zhangang Xiao
Proteolysis targeting chimera (PROTAC) presents a powerful strategy for targeted protein degradation (TPD). The heterobifunctional PROTAC molecule consists of an E3 ligase ligand covalently linked to a protein of interest (POI) via a linker. PROTAC can induce ubiquitinated proteasomal degradation of proteins by hijacking the ubiquitin-proteasome degradation system (UPS). This technique has the advantages of broad targeting profile, good cell permeability, tissue specificity, high selectivity, oral bioavailability, and controllability. To date, a growing number of PROTACs targeting gastrointestinal cancers have been successfully developed, and, in many cases, their POIs have been validated as clinical drug targets. To the best of our knowledge, 15 PROTACs against various targets are currently tested in clinical trials, and many more are likely to be added in the near future. Therefore, this paper details the mechanism, research progress, and application in clinical trials of PROTACs, and summarizes the research achievements related to PROTACs in gastrointestinal cancers. Finally, we discuss the advantages and potential challenges of PROTAC for cancer treatment.

22 March 2024 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
YZYao Zhang
Yao Zhang
XWXu Wu
Xu Wu
DLDan Li
Dan Li
RHRong Huang
Rong Huang
XDXiangyu Deng
Xiangyu Deng
QWQinglian Wen
Qinglian Wen
Background: Cervicovaginal microbiome plays an important role in the persistence of HPV infection and subsequent disease development. However, cervicovaginal microbiota varied cross populations with different habits and regions. Identification of population-specific biomarkers from cervicovaginal microbiota and host metabolome axis may support early detection or surveillance of HPV-induced cervical disease at all sites. Therefore, in the present study, to identify HPV-specific biomarkers, cervicovaginal secretion and serum samples from HPV-infected patients (HPV group, n = 25) and normal controls (normal group, n = 17) in Xichang, China were collected for microbiome (16S rRNA gene sequencing) and metabolome (UHPLC-MS/MS) analysis, respectively. Results: The results showed that key altered metabolites of 9,10-DiHOME, α-linolenic acid, ethylparaben, glycocholic acid, pipecolic acid, and 9,12,13-trihydroxy-10(E),15(Z)-octadecadienoic acid, correlating with Sneathia (Sneathia_amnii), Lactobacillus (Lactobacillus_iners), Atopobium, Mycoplasma, and Gardnerella, may be potential biomarkers of HPV infection. Conclusion: The results of current study would help to reveal the association of changes in cervicovaginal microbiota and serum metabolome with HPV infections.